Skip to main
ACET

ACET Stock Forecast & Price Target

ACET Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Adicet Bio Inc is a clinical-stage biotechnology company with promising potential driven by its allogeneic gamma delta T cell therapies, particularly the product candidate ADI-001, which exhibits significant efficacy in treating autoimmune diseases like lupus nephritis and systemic lupus erythematosus. The company is poised for expansion into oncology with the anticipated Ph1 study of ADI-212 targeting metastatic castration-resistant prostate cancer set to begin in 2026, potentially introducing new avenues for growth and value creation. Additionally, the planned collaboration with third-party manufacturers for commercial-scale production mitigates manufacturing risks, further supporting a positive outlook on the company’s operational stability and growth trajectory.

Bears say

Adicet Bio Inc faces a negative outlook primarily due to an anticipated net loss of $1.13 per share for 2025, coupled with the possibility that its lead product candidate, ADI-001, may underperform in efficacy compared to expectations, particularly in patients who have previously failed anti-CD20 therapies. There are significant concerns regarding the company's pipeline, with increased risks related to negative clinical data, prolonged developmental timelines, potential setbacks in later-stage studies, and challenges in obtaining regulatory approvals, which may lead to reduced commercial success and long-term dilution of shareholder value. Additionally, the company's probability of success for key indications has been downgraded, now standing at 15%, alongside a raised discount rate reflecting a more conservative financial stance.

ACET has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Adicet Bio, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Adicet Bio, Inc. (ACET) Forecast

Analysts have given ACET a Strong Buy based on their latest research and market trends.

According to 3 analysts, ACET has a Strong Buy consensus rating as of Mar 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Adicet Bio, Inc. (ACET)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.